Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc. develops telitacicept for autoimmune diseases, with company updates centered on clinical development, financing, governance and employee equity compensation. Telitacicept is described by the company as a dual BAFF/APRIL inhibitor and novel dual-target fusion protein for autoantibody-driven conditions, with global Phase 3 programs in generalized myasthenia gravis and primary Sjögren’s disease.
Recurring news includes clinical-trial starts and data discussions, financial results and balance-sheet updates, private-placement financing, board appointments, investor-conference presentations and Nasdaq inducement grants under the Vor Biopharma Inc. 2023 Inducement Plan. Company announcements also reflect telitacicept regulatory status in China and global development across major autoimmune indications.
Vor Bio (Nasdaq: VOR)/b) and partner RemeGen announced that China’s NMPA has approved for adult patients with Sjögren’s disease (SjD), the first and only approved SjD therapy in China.
The decision is based on a Phase 3 trial showing statistically significant ESSDAI and clinically meaningful ESSPRI improvements, with a favorable safety profile. This is the fifth approved indication for telitacicept.
Vor Bio (Nasdaq: VOR) and collaborator RemeGen announced that China’s NMPA has conditionally approved telitacicept for adult IgA nephropathy, the first BAFF/APRIL-targeting therapy for IgAN and the drug’s fourth approved indication.
Approval is based on Phase 2 and Phase 3 TELIGAN data showing a 59% UPCR reduction and favorable safety.
Vor Bio (Nasdaq: VOR) granted equity awards on June 1, 2026 to 10 newly hired employees under its 2023 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4).
The awards include stock options for 61,050 shares at $14.57 and RSUs for 12,900 shares, both vesting over four years.
Vor Bio (Nasdaq: VOR) will present a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Wednesday, June 3, 2026, from 9:55–10:25 a.m. ET, with a live webcast and 30-day replay on the Vor Bio investor website.
Vor Bio (Nasdaq: VOR) reported interim Phase 3 TELIGAN data for telitacicept in IgA nephropathy from a China trial published in NEJM.
Telitacicept achieved a 58.9% UPCR reduction vs 8.8% for placebo at week 39, with stable eGFR, favorable kidney outcomes, and generally consistent safety.
Vor Bio (Nasdaq: VOR) reported Q1 2026 results and a corporate update. Enrollment is ongoing in two global Phase 3 UPSTREAM trials of telitacicept for generalized myasthenia gravis and primary Sjögren’s disease, with gMG topline data expected in 1H 2027.
Cash and investments were $491.5 million on March 31, 2026, expected to fund operations into early 2029. Q1 2026 R&D expenses were $17.6 million versus $26.7 million a year earlier, while G&A expenses rose to $17.6 million from $6.6 million. Net loss widened to $219.6 million, mainly due to a change in the fair value of liability-classified warrants.
Vor Bio (Nasdaq: VOR) announced inducement awards on May 1, 2026: 53,400 stock options and 11,350 RSUs granted to six newly hired employees under the Vor Biopharma 2023 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).
Options have a 10-year term and an exercise price of $13.85 (closing price on grant date). Options vest 25% after 12 months, then monthly over 36 months; RSUs vest 25% after 12 months, then quarterly over 36 months, subject to continued employment.
Vor Bio (Nasdaq: VOR) announced inducement grants on April 1, 2026 for nine newly hired employees: 42,650 stock options and 9,050 RSUs under the 2023 Inducement Plan.
The options carry a $17.39 exercise price (closing price on grant date), a 10-year term, and a four-year vesting schedule (25% after 12 months, then monthly). RSUs vest over four years with 25% after 12 months and quarterly thereafter, all subject to continued employment and award agreements.
Vor Bio (NASDAQ: VOR) reported Q4 and full-year 2025 results and a corporate update. Key highlights: first patient dosed in global Phase 3 UPSTREAM SjD; $75.0 million private placement with TCGX on March 27, 2026; pro-forma cash and investments of $530.2 million as of Dec 31, 2025, projected to fund operations into early 2029. Vor expects topline gMG data in 1H 2027. 2025 R&D was $321.5M (up $228.2M YoY); 2025 G&A was $50.1M. Q4 2025 net income was $1,722.8M driven by warrant fair-value gains; full-year 2025 net loss was $696.0M.
Vor Bio (Nasdaq: VOR) announced dosing of the first patient in UPSTREAM SjD, a global Phase 3, randomized, double-blind, placebo-controlled trial of telitacicept for adult primary Sjögren’s disease.
The trial will enroll ~250 patients, use subcutaneous dosing, and has a primary endpoint of change in ESSDAI at Week 48. Prior Phase 3 data from late 2025 in China showed statistically significant improvements in ESSDAI and ESSPRI.